文献速递生殖医学

2014年欧洲辅助生殖技术:欧洲人类生殖与胚胎学会欧洲IVF监测联盟基于欧洲登记处的结果

ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE).
PubMed 文献 · Hum Reprod · 2018-01-01

欧洲人类生殖与胚胎学会欧洲IVF监测联盟第18次报告汇总39国1279家机构2014年776556个辅助生殖周期及26国IUI数据,显示治疗数量持续增长,IVF、ICSI、FER、ED妊娠率较2013年略有上升,IUI分娩率稳定,多胎分娩率略降。

要点

  • 2014年39国1279家机构共报告776556个辅助生殖周期,含IVF 146148、ICSI 362285、FER 192027、PGT 15894、ED 56516、IVM 292、FOR 3404。
  • IVF每采卵与每移植临床妊娠率分别为29.9%和35.8%,ICSI分别为28.4%和35.0%,均略高于2013年。
  • IVF与ICSI合计单胎、双胎、三胎分娩率分别为82.5%、17.0%、0.5%,双胎与三胎较2013年略降。

核心结论

  • 第18次ESHRE报告显示欧洲辅助生殖治疗数量持续增长,治疗方式多样性增加,在多数参与国对出生率的贡献上升。

研究设计与样本

  • 欧洲IVF监测联盟为ESHRE持续收集欧洲数据,2014年1月1日至12月31日治疗数据由39国国家登记处或诊所/专业学会自愿提供。
  • 来自39国1279家辅助生殖机构的776556个治疗周期,含IVF 146148、ICSI 362285、FER 192027、PGT 15894、ED 56516、IVM 292、FOR 3404。
  • IUI数据来自26国(IUI-H)和21国(IUI-D)共1364家机构,含IUI-H 120789个周期和IUI-D 49163个周期。

主要发现

  • IVF每采卵和每移植临床妊娠率2014年分别为29.9%和35.8%,2013年分别为29.6%和34.5%;ICSI分别为28.4%和35.0%,2013年分别为27.8%和32.9%。
  • FER妊娠率从2013年27.0%升至2014年27.6%;ED新鲜移植妊娠率50.3%(2013年49.8%),FOR妊娠率48.7%(2013年46.4%)。
  • IUI-H后分娩率8.5%(2013年8.6%),IUI-D后11.6%(2013年11.1%);IVF与ICSI合计移植1、2、3、≥4个胚胎分别占34.9%、54.5%、9.9%、0.7%(2013年分别为31.4%、56.3%、11.5%、1%)。
  • IVF与ICSI合计单胎、双胎、三胎分娩率分别为82.5%、17.0%、0.5%(2013年分别为82.0%、17.5%、0.5%);FER双胎和三胎分娩率分别为12.4%和0.3%(2013年分别为12.5%和0.3%);IUI-H后分别为9.5%和0.3%(2013年9.5%和0.6%),IUI-D后分别为7.7%和0.3%(2013年7.5%和0.3%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 欧洲各国数据收集和报告方法不同。
  • EIM接收各国汇总数据,完整性水平不一。
  • 一些国家的登记处未能提供关于启动周期数和分娩数的充分数据。
  • 只要提供的数据不完整,结果应谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What are the European trends and developments in ART and IUI in 2014 as compared to previous years? SUMMARY ANSWER: The 18th ESHRE report on ART shows a continuing expansion of both treatment numbers in Europe and more variability in treatment modalities resulting in a rising contribution to the birth rates in most participating countries. WHAT IS KNOWN ALREADY: Since 1997, ART data generated by national registries have been collected, analysed by the European IVF-monitoring (EIM) Consortium and reported in 17 manuscripts published in Human Reproduction. STUDY DESIGN, SIZE, DURATION: Continuous collection of European data by the EIM for ESHRE. The data for treatments performed in 2014 between 1 January and 31 December in 39 European countries were provided by national registries or on a voluntary basis by clinics or professional societies. PARTICIPANTS/MATERIALS, SETTING, METHODS: From 39 countries and 1279 institutions offering ART services, a total of 776 556 treatment cycles, involving 146 148 with IVF, 362 285 with ICSI, 192 027 with frozen embryo replacement (FER), 15 894 with PGT, 56 516 with egg donation (ED), 292 with IVM and 3404 with frozen oocyte replacement (FOR) were reported. European data on IUI using husband/partner's semen (IUI-H) and donor semen (IUI-D) were reported from 1364 institutions offering IUI in 26 countries and 21 countries, respectively. A total of 120 789 treatments with IUI-H and 49 163 treatments with IUI-D were included. MAIN RESULTS AND THE ROLE OF CHANCE: In 14 countries (17 in 2013), where all institutions contributed to their respective national registers, a total of 291 235 treatment cycles were performed in a population of ~208 million inhabitants, corresponding to 1925 cycles per million inhabitants (range: 423-2978 per million inhabitants). After treatment with IVF the clinical pregnancy rates (PR) per aspiration and per transfer were marginally higher in 2014 than in 2013, at 29.9 and 35.8% versus 29.6 and 34.5%, respectively. After treatment with ICSI the PR per aspiration and per transfer were also higher than those achieved in 2013 (28.4 and 35.0% versus 27.8 and 32.9%, respectively). After FER with own embryos the PR continued to rise, from 27.0% in 2013 to 27.6% in 2014. After ED a similar trend was observed with PR reaching 50.3% per fresh transfer (49.8% in 2013) and 48.7% for FOR (46.4% in 2013). The delivery rates (DR) after IUI remained stable at 8.5% after IUI-H (8.6% in 2013) and at 11.6% after IUI-D (11.1% in 2013). In IVF and ICSI together, 1, 2, 3 and ≥4 embryos were transferred in 34.9, 54.5, 9.9 and in 0.7% of all treatments, respectively (corresponding to 31.4%, 56.3, 11.5% and 1% in 2013). This evolution in embryo transfer strategy in both IVF and ICSI resulted in a singleton, twin and triplet DR of 82.5, 17.0 and 0.5%, respectively (compared to 82.0, 17.5 and 0.5%, respectively, in 2013). Treatments with FER in 2014 resulted in a twin and triplet DR of 12.4 and 0.3%, respectively (versus 12.5 and 0.3% in 2013). Twin and triplet DR after IUI were 9.5 and 0.3%, respectively, after IUI-H (in 2013:9.5 and 0.6%) and 7.7 and 0.3% after IUI-D (in 2013: 7.5 and 0.3%). LIMITATION, REASONS FOR CAUTION: The method of data collection and reporting varies among European countries. The EIM receives aggregated data from various countries with variable levels of completeness. Registries from a number of countries have failed to provide adequate data about the number of initiated cycles and deliveries. As long as incomplete data are provided, the results should be interpreted with caution. WIDER IMPLICATIONS OF THE FINDINGS: The 18th ESHRE report on ART shows a continuing expansion of treatment numbers in Europe. The number of treatments reported, the variability in treatment modalities and the rising contribution to the birth rates in most participating countries point towards the increasing impact of ART on reproduction in Europe. Being the largest data collection on ART, the report gives detailed information about ongoing developments in the field. STUDY FUNDING/COMPETING INTEREST(S): The study has no external funding and all costs are covered by ESHRE. There are no competing interests.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. De Geyter C, Calhaz-Jorge C, Kupka MS, et al. ART in Europe, 2014: results generated from European registries by ESHRE: The European IVF-monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod. 2018. PMID: 30032255. doi:10.1093/humrep/dey242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。